

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(於百慕達註冊成立之有限公司)

(Stock Code : 6108)

(股份代號:6108)

NOTIFICATION LETTER 通知信函

Dear Non-Registered Shareholder⁽¹⁾,

20 September 2023

New Ray Medicine International Holding Limited (the “Company”)

– Notification of publication of Interim Report 2023 of the Company (“Interim Report 2023”) on the Company’s website

The Interim Report 2023, in both English and Chinese versions, is available on the websites of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the Company at www.newraymedicine.com. You may access the Interim Report 2023 by clicking the <Investor Relations> section of the Company’s website.

If you wish to receive printed version of the Interim Report 2023, please complete the Request Form on the reverse side and return it to the Company’s Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the mailing label (for pre-paid postage in Hong Kong) at the bottom of the Request Form.

Please note that by completing and returning the Request Form to request for the printed version of the Interim Report 2023, we take that you would like to receive printed version for all future Corporate Communications⁽²⁾ of the Company to be sent to you until you notify the Company’s Share Registrar to the contrary or you cease to hold any shares of the Company.

Should you have any queries relating to this notification, please do not hesitate to call the enquiry hotline at (852) 2980 1333 from 9:00 a.m. to 5:00 p.m. (Monday to Friday, excluding public holidays).

On behalf of the Board

New Ray Medicine International Holding Limited

Wang Qiuqin

Chairman & Executive Director

Notes:

- (1) This notification letter is addressed to “Non-registered Shareholder”, which means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications.
- (2) “Corporate Communications” refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company’s securities, including but not limited to: (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各非登記股東⁽¹⁾：

新銳醫藥國際控股有限公司（「本公司」）

— 於本公司網站刊發二零二三年中期報告（「二零二三年中期報告」）之發佈通知

二零二三年中期報告均備有英文及中文版本，已登載於香港聯合交易所有限公司網站 www.hkexnews.hk 及本公司網站 www.newraymedicine.com。閣下可於本公司網站內的「投資者關係」項目內瀏覽二零二三年中期報告。

如閣下欲收取二零二三年中期報告之印刷本，請填妥本函背面之申請表格及使用申請表格底部隨附之郵寄標籤（已預付在香港投寄之郵費）寄回本公司之股份過戶登記處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓。

請注意，當閣下填寫及寄回申請表格以索取二零二三年中期報告之印刷本後，我們認為閣下欲收取印刷本之指示適用於本公司今後所有之公司通訊⁽²⁾，直至閣下通知本公司之股份過戶登記處另外之安排或停止持有本公司的股份。

閣下如就本通知有任何疑問，請於上午九時至下午五時（星期一至星期五，公眾假期除外），致電查詢熱線(852) 2980 1333。

代表董事會
新銳醫藥國際控股有限公司
主席兼執行董事
王秋勤

2023年9月20日

附註：

- (1) 此函件乃向本公司之非登記之股東（指股份存放於中央結算及交收系統的人士或公司，並透過香港中央結算有限公司不時向本公司發出通知，希望收取公司通訊）發出。
- (2) 「公司通訊」指由本公司發出或將予發出以供本公司任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格。

REQUEST FORM 申請表格

To: **New Ray Medicine International Holding Limited**
(Stock Code: 6108) (the "Company")
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

致: **新銳醫藥國際控股有限公司**
(股份代號: 6108) (「本公司」)
經卓佳證券登記有限公司
香港夏慤道16號
遠東金融中心17樓

I/We would like to receive the current and future Corporate Communications⁽¹⁾ in printed copy of the Company.
本人/吾等要求索取本公司本次及今後刊發之公司通訊⁽¹⁾之印刷本。

Signature:

簽署:

Date:

日期:

Name:

姓名:

(English英文)

(Chinese中文)

(in block letters 請以正楷填寫)

Contact

Phone

Number:

聯絡電話:

Notes 附註:

1. "Corporate Communications" refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities, including but not limited to: (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
「公司通訊」指由本公司發出或將予發出以供本公司任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格。
2. By completing and returning this Request Form to request for the printed copy of the Current Corporate Communication, you have expressly indicated that you prefer to receive all future Corporate Communications of the Company in printed copy.
當閣下填寫及寄回此申請表格以索取刊發之本次公司通訊印刷本後，即表示閣下確認擬收取本公司日後刊發的所有公司通訊的印刷本。

(Please cut along the dotted line 請沿虛線剪下)



Mailing Label 郵寄標籤

Please cut the mailing label and stick this on an envelope to return the Request Form to us.

No postage stamp is required for local mailing

當閣下寄回此表格時，請將此郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票

Tricor Investor Services Limited
卓佳證券登記有限公司
Freepost No.簡便回郵號碼: 10 GPO
Hong Kong 香港
New Ray Medicine International Holding
Limited (6108)